An HIV vaccine, once it becomes available, could reduce vulnerability to HIV among African-American women. The purpose of this study was to assess determinants of HIV vaccine acceptability among African-American women across hypothetical levels of vaccine efficacy. Participants were recruited from a hospital-based family planning clinic in Atlanta, GA serving low-income patients (N = 321). Data were collected from audio-computer assisted surveys administered in the clinic waiting room. Psychosocial survey items were guided by Risk Homeostasis Theory (RHT) and Social Cognitive Theory (SCT). Multivariate logistic regression was used to identify determinants of acceptability for two hypothetical HIV vaccines with 50% and 90% efficacy. Overall, 63% of participants would accept a vaccine with 50% efficacy and 85% would accept a vaccine with 90% efficacy. In multivariate analyses, odds of acceptability for a vaccine with 50% efficacy were higher among participants with greater perceived HIV vaccine benefits (AOR = 1.13, p < 0.001) and lower among participants with more than high school education (AOR = 0.47, p = 0.033) and greater perceived costs of HIV vaccination (AOR = 0.95, p = 0.010). Odds of acceptability for a vaccine with 90% efficacy were higher among participants with greater perceived costs of unprotected sex (AOR = 1.08, p = 0.026), HIV vaccine benefits (AOR = 1.23, p < 0.001) and self-efficacy for sex refusal (AOR = 1.11, p = 0.044). HIV vaccine acceptability was high, particularly for a vaccine with 90% efficacy. Findings suggest that demographic and psychosocial factors may impact acceptability of an eventual HIV vaccine. Once an HIV vaccine is available, interventions to maximize uptake may benefit from using RHT and SCT constructs to target relevant psychosocial factors, such as perceived benefits and perceived costs of vaccination.
References
[1]
Centers for Disease Control and Prevention. Nationally Notifiable Infectious Conditions.
[2]
Centers for Disease Control and Prevention. Cases of HIV Infection and AIDS in the United States and Dependent Areas, 2006. HIV/AIDS Surveillance Report; 2008; Vol. 18.
[3]
Centers for Disease Control and Prevention, Atlanta, GA, USA. HIV/AIDS Surveillance Reports;
[4]
Centers for Disease Control and Prevention. HIV Prevalence Estimates—United States, 2006. MMWR 2008, 57, 1073–1076.
[5]
Centers for Disease Control and Prevention. HIV among African Americans.
[6]
Centers for Disease Control and Prevention. Gonorrhea—CDC Fact Sheet.
[7]
Centers for Disease Control and Prevention. Chlamydia—CDC Fact Sheet.
[8]
Risser, W.L.; Bortot, A.T.; Benjamins, L.J.; Feldmann, J.M.; Barratt, M.S.; Eissa, M.A.; Risser, J.M. The epidemiology of sexually transmitted infections in adolescents. Semin. Pediatr. Infect. Dis. 2005, 16, 160–167, doi:10.1053/j.spid.2005.04.004.
[9]
Centers for Disease Control and Prevention. Genital Herpes Statistics. 2012.
[10]
Crepaz, N.; Marshall, K.J.; Aupont, L.W.; Jacobs, E.D.; Mizuno, Y.; Kay, L.S.; Jones, P.; McCree, D.H.; O’Leary, A. The efficacy of HIV/STI behavioral interventions for African American females in the United States: A meta-analysis. Am. J. Public Health 2009, 99, 2069–2078, doi:10.2105/AJPH.2008.139519.
[11]
Fauci, A.S. 25 years of HIV. Nature 2008, 453, 289–290.
[12]
Institute of Medicine, National Academy of Sciences, USA. Methodological Challenges in Biomedical HIV Prevention Trials; Lagakos, S.W., Gable, A.R., Eds.; The National Academies Press: Washington, DC, USA, 2008.
[13]
Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premsri, N.; Namwat, C.; de Souza, M.; Adams, E. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361, 2209–2220, doi:10.1056/NEJMoa0908492.
[14]
HIV Vaccine Trials Unit—Seattle. HIV Vaccine Studies. 2013. Available online: http://www.seattlevaccines.org/vaccine_studies.html/ (accessed on 1 March 2013).
[15]
Newman, P.A.; Logie, C. HIV vaccine acceptability: A systematic review and meta-analysis. AIDS 2010, 24, 1749–1756, doi:10.1097/QAD.0b013e32833adbe8.
[16]
Frew, P.M.; Crosby, R.A.; Salazar, L.F.; Gallinot, L.P.; Bryant, L.O.; Holtgrave, D.R. Acceptance of a potential HIV/AIDS vaccine among minority women. J. Natl. Med. Assoc. 2008, 100, 802–813.
[17]
Rudy, E.T.; Newman, P.A.; Duan, N.; Kelly, E.M.; Roberts, K.J.; Seiden, D.S. HIV vaccine acceptability among women at risk: Perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ. Prev. 2005, 17, 253–267, doi:10.1521/aeap.17.4.253.66529.
[18]
Williams, C.C.; Newman, P.A.; Sakamoto, I.; Massaquoi, N.A. HIV prevention risks for Black women in Canada. Soc. Sci. Med. 2009, 68, 12–20, doi:10.1016/j.socscimed.2008.09.043.
[19]
Kakinami, L.; Newman, P.A.; Lee, S.J.; Duan, N. Differences in HIV vaccine acceptability between genders. AIDS Care 2008, 20, 542–546, doi:10.1080/09540120701867180.
[20]
Newman, P.A.; Duan, N.; Rudy, E.T.; Roberts, K.J.; Swendeman, D. Posttrial HIV vaccine adoption: Concerns, motivators, and intentions among persons at risk for HIV. J. Acquir. Immune Defic. Syndr. 2004, 37, 1393–1403, doi:10.1097/01.qai.0000127064.84325.ad.
[21]
Crosby, R.A.; Holtgrave, D.R.; Bryant, L.; Frew, P.M. Factors associated with the acceptance of an AIDS vaccine: An exploratory study. Prev. Med. 2004, 39, 804–808, doi:10.1016/j.ypmed.2004.03.004.
[22]
Liau, A.; Zimet, G.D.; Fortenberry, J.D. Attitudes about human immunodeficiency virus immunization: The influence of health beliefs and vaccine characteristics. Sex. Transm. Dis. 1998, 25, 76–81, doi:10.1097/00007435-199802000-00004.
[23]
Zimet, G.D.; Liau, A.; Fortenberry, V.D. Health beliefs and intention to get immunized for HIV. J. Adolesc. Health 1997, 20, 354–359, doi:10.1016/S1054-139X(97)00031-1.
[24]
Webb, P.M.; Zimet, G.D.; Mays, R.; Fortenberry, J.D. HIV immunization: Acceptability and anticipated effects on sexual behavior among adolescents. J. Adolesc. Health 1999, 25, 320–322, doi:10.1016/S1054-139X(99)00066-X.
[25]
Liau, A.; Zimet, G.D. The acceptability of HIV immunization: Examining vaccine characteristics as determining factors. AIDS Care 2001, 13, 643–650, doi:10.1080/09540120120075275.
[26]
Berwick, D.M.; Murphy, J.M.; Goldman, P.A.; Ware, J.E.; Barsky, A.J.; Weinstein, M.C. Performance of a five-item mental health screening test. Med. Care 1991, 29, 169–176, doi:10.1097/00005650-199102000-00008.
[27]
Spitalnick, J.S.; DiClemente, R.J.; Wingood, G.M.; Crosby, R.A.; Milhausen, R.R.; Sales, J.M.; McCarty, F.; Rose, E.; Younge, S.N. Brief report: Sexual sensation seeking and its relationship to risky sexual behaviour among African–American adolescent females. J. Adolesc. 2007, 30, 165–173, doi:10.1016/j.adolescence.2006.10.002.
[28]
Zuckerman, M.; Kuhlman, D.; Joireman, J. A Comparison of 3 Structural Models for Personality—The Big 3, the Big 5, and the Alternative 5. J. Pers. Soc. Psychol. 1993, 65, 757–768, doi:10.1037/0022-3514.65.4.757.
[29]
Crockett, R.A.; Weinman, J.; Hankins, M.; Marteau, T. Time orientation and health-related behaviour: Measurement in general population samples. Psychol. Health 2009, 24, 333–350, doi:10.1080/08870440701813030.
[30]
Wilde, G.J. The Theory of Risk Homeostasis: Implications for Safety and Health. Risk Anal. 1982, 2, 209–225, doi:10.1111/j.1539-6924.1982.tb01384.x.
[31]
Eaton, L.A.; Kalichman, S. Risk compensation in HIV prevention: Implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr. HIV/AIDS Rep. 2007, 4, 165–172.
[32]
Bandura, A. Social Learning Theory; Prentice Hall: Englewood Cliffs, NJ, USA, 1977.
Painter, J.E.; Borba, C.P.; Hynes, M.; Mays, D.; Glanz, K. The use of theory in health behavior research from 2000 to 2005: A systematic review. Ann. Behav. Med. 2008, 35, 358–362, doi:10.1007/s12160-008-9042-y.
[35]
Sales, J.M.; Spitalnick, J.; Milhausen, R.R.; Wingood, G.M.; DiClemente, R.J.; Salazar, L.F.; Crosby, R.A. Validation of the worry about sexual outcomes scale for use in STI/HIV prevention interventions for adolescent females. Health Educ. Res. 2009, 24, 140–152.
[36]
DiClemente, R.; Wingood, G.; Harrington, K.; Lang, D.; Davies, S.; Hook, E., 3rd.; Oh, M.; Crosby, R.; Hertzberg, V.; Gordon, A.B.; et al. Efficacy of an HIV prevention intervention for African American adolescent girls: A randomized controlled trial. JAMA 2004, 292, 171–179, doi:10.1001/jama.292.2.171.
[37]
Wingood, G.; DiClemente, R. Partner influences and gender-related factors associated with noncondom use among young adult African American women. Am. J. Community Psychol. 1998, 26, 29–51.
[38]
Newman, P.A.; Duan, N.; Lee, S.J.; Rudy, E.T.; Seiden, D.S.; Kakinami, L.; Cunningham, W.E. HIV vaccine acceptability among communities at risk: The impact of vaccine characteristics. Vaccine 2006, 24, 2094–2101, doi:10.1016/j.vaccine.2005.11.013.
[39]
Zimet, G.D.; Blythe, M.J.; Fortenberry, J.D. Vaccine characteristics and acceptability of HIV immunization among adolescents. Int. J. STD AIDS 2000, 11, 143–149, doi:10.1258/0956462001915570.
[40]
Ajzen, I.; Madden, T. Prediction of Goal-Directed Behavior: Attitudes, Intentions, and Perceived Behavioral Control. J. Exp. Soc. Psychol. 1986, 22, 453–474.
[41]
Parsons, J.T.; Halkitis, P.N.; Bimbi, D.; Borkowski, T. Perceptions of the benefits and costs associated with condom use and unprotected sex among late adolescent college students. J. Adolesc. 2000, 23, 377–391.
[42]
Parsons, J.T.; Siegel, A.W.; Cousins, J.H. Late adolescent risk-taking: Effects of perceived benefits and perceived risks on behavioral intentions and behavioral change. J. Adolesc. 1997, 20, 381–392, doi:10.1006/jado.1997.0094.
[43]
Salazar, L.F.; DiClemente, R.J.; Wingood, G.M.; Crosby, R.A.; Harrington, K.; Davies, S.; Hook, E.W.; Oh, M.K. Self-concept and adolescents refusal of unprotected sex: A test of mediating mechanisms among African American girls. Prev. Sci. 2004, 5, 137–149, doi:10.1023/B:PREV.0000037638.20810.01.
